Research Article

Antithrombotic Therapy Improves ICU Mortality of Septic Patients with Peripheral Vascular Disease

Shiqi Yuan,1 Chong Chen,2 Fengshuo Xu,3,4 Didi Han,3,4 Rui Yang,3,4 Shuai Zheng,2 Mengmeng Qiao,2 Xiaxuan Huang,1 and Jun Lyu3

1Department of Neurology, The First Affiliated Hospital of Jinan University, No. 613, Huangpu Road West, Guangzhou, Guangdong Province 510630, China
2School of Public Health, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China
3Department of Clinical Research, The First Affiliated Hospital of Jinan University, No. 613, Huangpu Road West, Guangzhou, Guangdong Province 510630, China
4School of Public Health, Xi’an Jiaotong University Health Science Center, Shaanxi Province 710061, China

Correspondence should be addressed to Jun Lyu; lyujun2020@jnu.edu.cn

Received 16 November 2021; Accepted 3 March 2022; Published 16 March 2022

Academic Editor: Sorin Hostiuc

Copyright © 2022 Shiqi Yuan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The effectiveness of antithrombotic drugs for treating sepsis is controversial. Here, we explore the association between antithrombotic therapy and intensive care unit (ICU) mortality for septic patients with peripheral vascular disease. Methods. This retrospective cohort study uses data from the Medical Information Mart for Intensive Care (MIMIC)-IIIdatabase. Kaplan–Meier survival analyses were used to examine mortality among different groups. Cox regression and marginal structural Cox models (MSCMs) were used to adjust for confounding factors. Main Results. The final cohort from the MIMIC-III database included 776 patients, of which 701 survived and 75 perished. The anticoagulant (AC) group and the antiplatelet-anticoagulation (AC-AP) group survived better than the group without antithrombotic treatment (non-AT). The AC and AC-AP groups showed a 0.363-fold and 0.373-fold risk of ICU mortality, respectively, compared with the non-AT group when controlling for age, gender, CRRT, alcohol, heart failure, hypertension, diabetes, obesity, renal failure, liver disease, INR, PT, PPT, and SpO2. Antiplatelet therapy did not reduce ICU mortality. The same trends were apparent from the MSCM. In addition, the AC-AP group exhibited a lower risk of bleeding complications. Conclusion. Although the antithrombotic group (AC and AC-AP groups) demonstrated a higher se-quential organ failure assessment (SOFA) score than the group without antithrombotic treatment (non-AT group), the risk of ICU mortality was lower without increasing the risk of bleeding complications. Our study further suggested that anticoagulation therapy may benefit the prognosis of septic patients with peripheral vascular disease.

1. Introduction

Sepsis is a severe disease characterized by organ dysfunction and dysregulation of the body’s inflammatory response to infection [1]. Around the world, sepsis causes almost 50 million cases with more than 11 million deaths annually [2]. Typically, sepsis is treated using antibiotic therapy, infection control, supportive care, and, in extreme cases, organ function replacement [3]. Activation of the clotting system and inflammation is necessary for the body’s defense during sepsis [4]; however, septic patients generally demonstrate abnormal coagulation [3]. The three main causes of sepsis-associated coagulation dysfunction and disseminated intravascular coagulation (DIC) are coagulation activation, platelet and other inflammatory cell activation, and vascular endothelial injury [5].

While studies are currently exploring the treatment of coagulation dysfunction for sepsis recovery, anticoagulant therapy remains controversial [6–9]. Alopodigrel and clopidoogrel are a widely used antiplatelet drug for cardiovascular diseases [10]. Platelet-endothelial cell and platelet-neutrophil interactions caused by platelet activation play a crucial role in microthrombosis and the release of inflammatory factors in patients with sepsis [11, 12]. However, studies on the effect of
antiplatelet agents on the prognosis of patients with sepsis have produced conflicting results [13]. The conflicting efficacy of antithrombotic drugs in sepsis is likely related to the selection of the study population. Moreover, widespread peripheral vascular disease in the population increases the risk of various cardiovascular events [14–16].

In this study, we aimed to investigate the correlation between antithrombotic therapy and ICU mortality in septic patients with peripheral vascular disease.

2. Materials and Methods

2.1. Setting. The era of big data has provided unprecedented opportunities for investigating critically ill patients [17]. A large intensive care database named Intensive Care Medical Information Marketplace (MIMIC-III) was used in this study. Descriptions of MIMIC-III can be found in previous studies [18, 19]. Briefly, MIMIC-III contains data related to the hospitalizations of 53,423 adult patients (16 years of age or older) treated to the intensive care unit (ICU) between 2001 and 2012. An average of 380 laboratory measurements and 4579 chart observations were obtained for each hospitalization.

2.2. Participants. Infected patients with a sequential organ failure assessment (SOFA) score of at least 2 (“septic” patients as defined by the latest septic-3 diagnostic criteria) [20, 21] and peripheral vasculopathy were included in our study. Infection and bleeding complications were identified using ICD-9 code, and peripheral vascular disease was screened for comorbidities. Because small number of patients may be admitted to the ICU multiple times, only patients admitted to the ICU for the first time were included in the analysis. Follow-up time was days of ICU admission, and survival status is the status at ICU discharge. The final cohort included 776 patients, of whom 701 were survivors and 75 were nonsurvivors.

2.3. Variable Extraction. We extracted the following patient information from the MIMIC-III database: age at admission, obesity, history of alcoholism gender, sequential organ failure assessment (SOFA) score, continuous renal replacement therapy (CRRT), history of hypertension, diabetes, renal failure, and liver disease. International normalized ratio (INR), prothrombin time (PT), partial thromboplastin time (PTT), and SpO2 were initial measurements selected for the laboratory examination.

3. Statistical Analysis

The study population was divided into groups with antithrombotic treatment, including antiplatelet (AP), anticoagulant (AC), and antiplatelet-anticoagulation (AC-AP) groups, and groups without antithrombotic treatment (non-AT group) based on treatment received at ICU admission. The AP, AC, and AC-AP groups include those on alopindogrel or clopidogrel, on low molecular-weight heparin, and on both antiplatelet (alopindogrel or clopidogrel) and anticoagulant drugs (low-molecular-weight heparin, LMWH), respectively. The covariates of different groups were compared using an appropriate chi-square or Fisher’s exact test. Continuous variables are represented by mean (standard deviation) or median (interquartile (IQR)) [22].

All statistical analyses were performed using the R package (version 4.1.0). Results were considered statistically significant at a $p$ value of $<0.05$. A Kaplan–Meier survival curve analysis was used to examine differences in ICU mortality among groups (citation needed). Log-rank tests were used to compare differences among groups further (citation needed). Cox proportional risk regression models were used to analyze effects of multiple factors on survival time and status (citation needed). The marginal structural Cox model (MSCM) was used to explain the basic line, time-dependent covariates, and history of antithrombotic drug use. Antithrombotic therapy during ICU hospitalization was considered a time-dependent variable of the MSCM. The parameter of the MSCM can be estimated by taking inverse probability weighting (IPW) in the form of correcting for confusion and selection bias [23]. The package ’IPW’ was used to estimate the weight of inverse probability [24].

4. Results

4.1. Baseline Differences between Groups. The final cohort included 776 sepsis patients with peripheral vascular disease, of whom 701 were survivors and 75 were nonsurvivors.

Summary statistics of the covariates of interest for different groups are listed in Table 1. Among the different groups, differences were found in patient’s SOFA score and hypertension ($p < 0.05$). The three antithrombotic treatment groups demonstrated higher SOFA scores than the non-AT group ($p < 0.05$). Among-group comparison after IPW indicated that there was no difference in these variables across treatments ($p > 0.05$) (Table S1).

4.2. Kaplan–Meier Survival Curve Showed the Risk of ICU Mortality among the Different Groups. The antithrombotic therapy groups (AC and AC-AP groups) survived better than the non-AT group ($p < 0.001$) (Figure 1(a)). However, there was no difference in survival between AC and AC-AP groups ($p > 0.05$). We further analyzed the K–M curve after IPW, and the K–M curve for the four groups exhibited same trend compared with that without IPW (Figure 1(b)).

4.3. Cox Risk Regression Model Was Used to Analyze Effects of Multivariate Variables on Survival Time and Outcome. We used the Cox proportional risk regression model and MSCM to investigate the effect of multivariate variables on survival time and outcomes further and estimate the hazard ratio (HR) of ICU mortality. As shown in Figure 2, the AC group showed a 0.363-fold risk of ICU mortality (HR = 0.363; 95% CI: 0.188–0.721, $p = 0.004$) and the AC-AP group exhibited a 0.373-fold risk of ICU mortality (HR = 0.373; 95% CI: 0.209–0.667, $p < 0.001$) compared with the non-AT group. Similar conclusions were obtained from the MSCM analysis.
Table 1: Characteristics among groups before IPW. AP, antiplatelet group; AC, anticoagulant group; AC-AP, antiplatelet-anticoagulation group; and non-AT, the group that did not receive antithrombotic treatment.

| Characteristics          | Non-AT group | AP group | AC group | AC-AP group | P value |
|--------------------------|--------------|----------|----------|-------------|---------|
| Age (median, IQR)        | 75.5 (66.8, 83.3) | 73.6 (66.5, 80.7) | 74.3 (62.5, 83) | 73.7 (65.4, 81.2) | 0.196 |
| Gender (n, %)            |              |          |          |             | 0.608 |
| Female                   | 89 (43.4)    | 57 (42.5) | 80 (49.1) | 128 (46.7) |         |
| Male                     | 116 (56.6)   | 77 (57.5) | 83 (50.9) | 146 (53.3) |         |
| CRRT (n, %)              |              |          |          |             | 0.324 |
| No                       | 198 (96.6)   | 130 (97)  | 152 (93.3) | 259 (94.5) |         |
| Yes                      | 7 (3.4)      | 4 (3)     | 11 (6.7)  | 15 (5.5)    |         |
| Alcoholism (n, %)        |              |          |          |             | 0.054 |
| No                       | 199 (97.1)   | 128 (95.5) | 150 (92)  | 266 (97.1) |         |
| Yes                      | 6 (2.9)      | 6 (4.5)   | 13 (8)    | 8 (2.9)     |         |
| Heart failure (n, %)     |              |          |          |             | 0.537 |
| No                       | 94 (45.9)    | 65 (48.5) | 76 (46.6) | 114 (41.6) |         |
| Yes                      | 111 (54.1)   | 69 (51.5) | 87 (53.4) | 160 (58.4) |         |
| Hypertension (n, %)      |              |          |          |             | 0.024 |
| No                       | 67 (32.7)    | 27 (20.1) | 47 (28.8) | 62 (22.6)  |         |
| Yes                      | 138 (67.3)   | 107 (79.9)| 116 (71.2)| 212 (77.4) |         |
| Diabetes (n, %)          |              |          |          |             | 0.319 |
| No                       | 104 (50.7)   | 68 (50.7) | 93 (57.1) | 131 (47.8) |         |
| Yes                      | 101 (49.3)   | 66 (49.3) | 70 (42.9) | 143 (52.2) |         |
| Obesity (n, %)           |              |          |          |             | 0.175 |
| No                       | 193 (94.1)   | 123 (91.8)| 156 (95.7)| 248 (90.5) |         |
| Yes                      | 12 (5.9)     | 11 (8.2)  | 7 (4.3)   | 26 (9.5)    |         |
| Renal failure (n, %)     |              |          |          |             | 0.274 |
| No                       | 114 (55.6)   | 88 (65.7) | 97 (59.5) | 156 (56.9) |         |
| Yes                      | 91 (44.4)    | 46 (34.3) | 66 (40.5) | 118 (43.1) |         |
| Liver disease (n, %)     |              |          |          |             | 0.573 |
| No                       | 190 (92.7)   | 123 (91.8)| 145 (89) | 253 (92.3) |         |
| Yes                      | 15 (7.3)     | 11 (8.2)  | 18 (11)   | 21 (7.7)    |         |
| Sofa (median, IQR)       | 4 (3, 6)     | 6 (4, 7)  | 5 (3.5, 7)| 5 (3, 7.8)  | 0.013 |
| INR (median, IQR)        | 1.2 (1.1, 1.5)| 1.2 (1.1, 1.6)| 1.3 (1.1, 1.8)| 1.2 (1.1, 1.6) | 0.668 |
| PT (median, IQR)         | 13.9 (12.9, 16.1)| 14.3 (12.9, 16.7)| 14.5 (12.9, 19.1)| 13.9 (12.8, 16.8) | 0.398 |
| PPT (median, IQR)        | 30.1 (26.5, 36)| 32 (26.4, 39.1)| 30.8 (26.9, 36.9)| 30.4 (26.4, 38) | 0.561 |
| SpO2 (median, IQR)       | 97.2 (96, 98.5)| 97.9 (96.5, 98.8)| 97.7 (96.4, 98.7) | 97.6 (96.2, 98.7) | 0.086 |

Figure 1: The Kaplan–Meier survival curve showing the risk of ICU mortality among the different groups ((a) before IPW, (b) after IPW). AP, antiplatelet group; AC, anticoagulant group; AC-AP, antiplatelet-anticoagulation group. The reference group was patients that did not receive antithrombotic treatment (non-AT group). IPW, inverse probability weighting. The log-rank test was used to further compare the differences among the groups.
Bleeding emerged as a common complication of antithrombotic therapy; as such, we further studied the bleeding complications among different groups. The AC-AP group had a lower bleeding complication risk than the non-AT group (p < 0.001) (Figure 3(a)). Even after adjusting for multiple confounders, the AC-AP group still was at lower risk for bleeding complications (HR = 0.352; 95% CI: 0.197–0.628, p < 0.001) (Figure 3(b)).

Overall, our results suggested that anticoagulant therapy could substantially reduce ICU mortality without increasing the risk of bleeding complications in septic patients with peripheral vascular disease.

5. Discussion

The coagulation system is often activated in severe septic patients. Inflammation can incite the activation of the coagulation system, but coagulation also can activate inflammation [25]. The primary pathways leading to septicemia-induced coagulation and DIC include activation of the coagulation system, platelets, and other inflammatory cells (e.g., neutrophils and lymphocytes). Furthermore, sepsis can also cause vascular endothelial injury [5, 26], leading to multiple organ failure [27] and peripheral artery disease (PAD). Atherosclerosis is a common pathophysiological process in CAD and PAD. In atherosclerosis, vascular injury exposes the subcutaneous matrix, and platelet adhesion, activation, and aggregation (platelet-platelet and platelet-monocyte) can create lesions and lead to thrombotic complication (atherothrombosis) [28]. Therefore, sepsis-associated patients with peripheral vascular disease may be prone to abnormal coagulation.

We observed that antithrombotic therapy was associated with greater survival in sepsis patients with peripheral vascular disease compared to those lacking antithrombotic therapy, even when patients without therapy were admitted to the...
ICU with higher incidence of organ failure than other antithrombotic therapy groups. In addition, our results suggested that anticoagulant therapy can substantially reduce ICU mortality without increasing the risk of bleeding complications for these patients. As such, our results suggest that anticoagulation therapy may improve the prognosis of septic patients with peripheral vascular disease.

This study presented the advantages of using the MSCM statistical method, considering both baseline and time-varying confusions, susceptibility of coagulation indexes of ICU patients to change, and time-dependent course of antithrombotic drug use depending on indexes of coagulation function and platelets measured in advance. Therefore, it produced a complex and dynamic relationship. The MSCM model had also been successfully applied to other time-dependent intervention studies [22, 29]. Unfortunately, the database did not provide the purpose for using low-molecular-weight heparin (LMWH). Therefore, scatter plot analysis was performed based on the dose of LMWH used by each participant. As shown in Figure S1 of supplementary materials, most participants received 5000 IU of LMWH for each dose, while a small number of participants received multiple doses during the same hospitalization (Figure S1). Although the database did not provide the purpose of LMWH use, 5000 IU daily LMWH appeared to be an appropriate prophylactic dose based on clinical practice of LMWH use.

We note the following limitations to this work. First, this study was focused on septic patients with peripheral vascular disease; however, individualized antithrombotic therapy may also improve the prognosis of patients. Second, we only examined the effects of antithrombotic drugs (alopidogrel, clopidogrel, and LMWH) while antiplatelet (indobufen, and prasugrel) and anticoagulant (rivaroxaban, and dabigatran) medications were not included in our study. As novel antithrombotic drugs in septic patients with peripheral vascular may inhibit thrombosis and bleeding risk [30, 31], prospective studies on the effects of these drugs on this pool of patients should be conducted.

6. Conclusion

Although the antithrombotic group (AC and AC-AP groups) demonstrated higher SOFA scores than the group without antithrombotic treatment (non-AT group), the risk of ICU mortality was lower without increasing the risk of bleeding complications. Our study suggests that anticoagulation therapy may improve the prognosis of septic patients with peripheral vascular disease and that individualized treatment may be a future direction.

Data Availability

The MIMIC-III data were available on the project website at https://mimic.mit.edu. MIMIC database data requires database permissions, so we cannot release it to unauthorized researchers. However, if other researchers gain access to MIMIC database, we can provide the research data extracted from the MIMIC database via e-mail upon reasonable request.

Ethical Approval

The establishment of the MIMIC-III database was approved by the Massachusetts Institute of Technology (Cambridge, MA) and Beth Israel Deaconess Medical Center (Boston, MA). Ethical approval was therefore waived for studies using this database.

Consent

Consent was obtained for the original data collection. Need for informed consent was waived for studies using this database.

Disclosure

Shiqi Yuan and Chong Chen should be considered the co-first authors.

Conflicts of Interest

The authors have no conflicts of interest to disclose.

Authors’ Contributions

Jun Lyu conceptualized the research aims and planned the analyses. Shiqi Yuan and Chong Chen guided the literature review, wrote the first draft of the paper, and contributed equally to this study. Fengshuo Xu, Didi Han, and Rui Yang extracted the data from the MIMIC-III database. Shiqi Yuan, Shuai Zheng, Mengmeng Qiao, and Xiaxuan Huang participated in data analysis and interpretation. The other authors provided comments and approved the final manuscript.

Acknowledgments

The authors would like to thank the Massachusetts Institute of Technology and the Beth Israel Deaconess Medical Center for the MIMIC project.

Supplementary Materials

Table S1: characteristics among groups after IPW. Figure S1: scatter plot of low-molecular-weight heparin dose per use for each participant. (Supplementary Materials)

References

[1] K.-M. Kaukonen, M. Bailey, S. Suzuki, D. Pilcher, and R. Bellomo, "Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012," JAMA, vol. 311, no. 13, pp. 1308–1316, 2014.
[2] K. E. Rudd, S. C. Johnson, K. M. Agesa et al., "Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study," The Lancet, vol. 395, no. 10219, pp. 200–211, 2020.
[3] M. Levi, M. Schulz, and T. van der Poll, "Sepsis and thrombosis," Seminars in Thrombosis and Hemostasis, vol. 39, pp. 559–566, 2013.
[4] T. Iba, M. Levi, and J. H Levy, “Sepsis-induced coagulopathy and disseminated intravascular coagulation,” *Seminars in Thrombosis and Hemostasis*, vol. 46, pp. 89–95, 2020.

[5] T. Iba, J. H Levy, A. Raj, and T. E. Warkentin, “Advance in the management of sepsis-induced coagulopathy and disseminated intravascular coagulation,” *Journal of Clinical Medicine*, vol. 8, 2019.

[6] B. Gärdlund, “Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group,” *Lancet (London, England)*, vol. 347, pp. 1357–1361, 1996.

[7] K. Yamakawa, Y. Umemura, Y. Umemura et al., “Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan,” *Critical Care*, vol. 20, no. 1, p. 229, 2016.

[8] R. E. V. de Castro, D. N. M. Medeiros, A. Prata-Barbosa, and M. C. de Magalhães-Barbosa, “Surviving sepsis campaig national guidelines for the management of septic shock and sepsis-associated organ dysfunction in children,” *Pediatric Critical Care Medicine*, vol. 21, no. 10, pp. 924-925, 2020.

[9] T. van der Poll and S. M. Opal, “Should all septic patients be given systemic anticoagulation? No,” *Intensive Care Medicine*, vol. 43, no. 3, pp. 455–457, 2017.

[10] H. Hoshino, K. Toyoda, K. Omae, N. Ishida, S. Uchiyama, and K. Kimura, “Dual antiplatelet therapy using cilostazol with aspirin or Clopidogrel: subanalysis of the CSPS.com trial,” *Stroke*, vol. 52, Article ID A121034378, 2021.

[11] J. Li, K. Kim, K. Kim, A. Barazia, A. Tseng, and J. Cho, “Platelet-neutrophil interactions under thromboinflammatory conditions,” *Cellular and Molecular Life Sciences*, vol. 72, no. 14, pp. 2627–2643, 2015.

[12] Y. Wang, Y. Ouyang, B. Liu, X. Ma, and R. Ding, “Platelet activation and antiplatelet therapy in sepsis: a narrative review,” *Thrombosis Research*, vol. 166, pp. 28–36, 2018.

[13] Y. Ouyang, Y. Wang, B. Liu, X. Ma, and R. Ding, “Effects of antiplatelet therapy on the mortality rate of patients with sepsis: a meta-analysis,” *Journal of Critical Care*, vol. 50, pp. 162–168, 2019.

[14] M. H. Criqui, K. Matsuhashita, V. Aboyans, C. N. Hess, C. W. Hicks, and T. W. Kwan, “Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American heart association,” *Circulation*, vol. 144, p. R1005, 2021.

[15] V. Barrios, P. Beato, C. Brotons, R. Campusuzo, J. F. Merino-Torres, and J. M. Mostaza, “Comprehensive management of risk factors in peripheral vascular disease,” *Expert consensus*. *Rev Clin Esp (Barc)*, vol. 222, 2021.

[16] N. J. Leeper and N. M. Hamburg, “Peripheral vascular disease in 2021,” *Circulation Research*, vol. 128, no. 12, pp. 1803-1804, 2021.

[17] J. Yang, Y. Li, Q. Liu et al., “Brief introduction of medical database and data mining technology in big data era,” *Journal of Evidence-Based Medicine*, vol. 13, no. 1, pp. 57–69, 2020.

[18] A. E. W. Johnson, T. J. Pollard, L. Shen et al., “MIMIC-III, a freely accessible critical care database,” *Scientific Data*, vol. 3, no. 1. Article ID 160035, 2016.

[19] W.-T. Wu, Y.-J. Li, A.-Z. Feng et al., “Data mining in clinical big data: the frequently used databases, steps, and methodological models,” *Military Medical Research*, vol. 8, no. 1, p. 44, 2021.

[20] C. Li, Y. Xie, Z. Zheng, K. Xu, N. Zhu, and X. Zang, “Effect of Jiedu Limai decoction in septic patients with syndrome of heat-toxin exuberance,” *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue*, vol. 33, pp. 815–820, 2021.

[21] M. Singer, C. S. Deutschman, C. W. Seymour et al., “The third international consensus definitions for sepsis and septic shock (Sepsis-3),” *JAMA*, vol. 315, no. 8, pp. 801–810, 2016.

[22] Z. Zhang, C. Zhub, L. Mo, and Y. Hong, “Effectiveness of sodium bicarbonate infusion on mortality in septic patients with metabolic acidosis,” *Intensive Care Medicine*, vol. 44, no. 11, pp. 1888–1895, 2018.

[23] J. M. Robins, M. A. Hernán, and B. Brumback, “Marginal structural models and causal inference in epidemiology,” *Epidemiology*, vol. 11, no. 5, pp. 550–560, 2000.

[24] R. B. Geskus and M. Willem, “Ipiw: an R package for inverse probability weighting,” *J STAT SOFTW*, vol. 43, 2011.

[25] M. Levi and T. Poll, “Coagulation in patients with severe sepsis,” *Seminars in Thrombosis and Hemostasis*, vol. 41, pp. 9–15, 2015.

[26] T. Iba and J. H. Levy, “Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis,” *Journal of Thrombosis and Haemostasis*, vol. 16, no. 2, pp. 231–241, 2018.

[27] S. Gando, M. Levi, and C.-H. Toh, “Disseminated intravascular coagulation,” *Nature Reviews Disease Primers*, vol. 2, no. 1, p. 16037, 2016.

[28] P. A. Gurbel, K. A. A. Fox, U. S. Tantry, H. ten Cate, and J. I. Weitz, “Combination antiplatelet and oral anticoagulant therapy in patients with coronary and peripheral artery disease,” *Circulation*, vol. 139, no. 18, pp. 2170–2185, 2019.

[29] C. Dupuis, M. Garrouste-Orgeas, S. Bailly et al., “Effect of transfusion on mortality and other adverse events among critically ill septic patients,” *Critical Care Medicine*, vol. 45, no. 12, pp. 1972–1980, 2017.

[30] B. Zwart, W. A. E. Parker, and R. F. Storey, “New antithrombotic drugs in acute coronary syndrome,” *Journal of Clinical Medicine*, vol. 9, 2020.

[31] E. F. Plow, Y. Wang, and D. I. Simon, “The search for new antithrombotic mechanisms and therapies that may spare hemostasis,” *Blood*, vol. 131, no. 17, pp. 1899–1902, 2018.